ROS1 and non-small cell lung carcinoma: Entrectinib has emerged as a promising therapeutic option for patients with NTRK fusion-positive solid tumours and ROS1-positive NSCLC, as demonstrated by findings from the ALKA-372-001, STARTRK-1, and STARTRK-2 studies.